• Home
• Services
• Bioconjugate Drug Development & Manufacturing
• Protein-Small Molecule Drug Conjugate

Protein-Small Molecule Drug Conjugate

CellMosaic® offers research and development services for biopharmaceutical companies developing recombinant proteins as therapeutics. Target-specific protein drugs can be created by conjugating drugs or toxins to recombinant proteins. We can also chemically modify or process your recombinant proteins with PEG or other classical polymers to enhance clinical performance. CellMosaic’s scientists have extensive experience in protein conjugation, purification, and modification.

For proteins that can be engineered at the molecular level, we recommend cysteine mutagenesis to introduce a precise, well-defined labeling site. For proteins that cannot be genetically modified, we identify specific sites that can be chemically targeted for site-specific labeling. When site-specific options are not available, we employ controlled labeling of surface amines combined with advanced purification techniques to generate single-ratio conjugates or highly homogeneous multi-ratio conjugates. 

Advantages of CellMosaic's protein conjugation strategy:

• Flexibility to attach drugs using mulitiple conjugation methods.
• Conjugation strategies can be easily adapted for different categories of compounds.
• Short development timelines for creating a customized bioconjugation strategy.

Case Studies:

1. Developing protein-irinotecan drug conjugate for a bio-pharmaceutical company at CellMosaic (shown below): need to conjugate with a very hydrophobic drug. The protein itself is not very stable and easily precipitated after being conjugated. Manage to obtain clean protein-drug conjugate with minimum aggregation. The conjugate shows a characteristic UV spectrum of irinotecan with absorbance maximum at 360 nm.